Key Highlights

● ALGN closed at $142.71 on 9 October 2026, and published averages of about $199 appear out of step with recent named targets of $155 to $209.

● Evercore downgraded the shares to In-Line on 5 October with a $155 target, and Stifel cut its target to $175 from $210 on 9 October.

● Market data shows one Strong Buy, eight Buy and seven Hold ratings from 16 analysts, with no Sell.

● UBS holds a $189 target at Neutral and BMO Capital Markets a $209 target at Outperform, both set in July.

Align Technology, Inc. (NASDAQ:ALGN), maker of the Invisalign clear aligner system, is a member of the S&P 500. Its shares closed at $142.71 on Friday 9 October 2026, after Evercore downgraded the stock and Stifel cut its target in the first days of October.

What Is the Latest Analyst Price Target?

Both data sets display an average of about $199, but that figure appears not to reflect a number of recent cuts, and it sits well above most of the targets that named brokers have published in recent weeks, so no consensus figure is presented here.

The named broker targets give a better guide to current thinking. Evercore's is $155, Stifel's is $175, UBS's is $189 and BMO Capital Markets' is $209.

What Are Wall Street Analysts Saying?

Ratings are split between positive and neutral views. The table shows one Strong Buy, eight Buy, seven Hold and no Sell ratings from 16 analysts. The second data set, using third-party data, shows six Strong Buy, three Buy, six Hold and one Sell. The two data sets count ratings differently.

The latest named actions point downwards. On 9 October Stifel Nicolaus kept its Buy rating but lowered its target from $210 to $175. On 5 October Evercore downgraded the shares from Outperform to In-Line and set a $155 target; the second data set records the previous Evercore target as $220. Raymond James reiterated a Buy rating on 5 October. In July UBS reiterated a Neutral rating with a $189 target, Needham & Co. Reiterated Hold, and BMO Capital Markets listed an Outperform rating with a $209 target.

What Could Help the Stock Reach the Price Target?

Recovery in demand for clear aligner treatments, steady case volumes and better margins would all be viewed positively.

A clearer explanation from management of the factors behind the recent downgrades and target cuts might also help investors, as might stronger quarterly results.

What Could Prevent the Stock Reaching the Target?

Competition from other aligner providers and from lower-priced alternatives is a long-standing concern for the sector. Consumer spending on elective dental treatment can be sensitive to economic conditions, and currency movements affect a company with international sales.

The recent cut-and-downgrade pattern is itself a risk, because further reductions from other brokers could pull the average down. The hold-rated analysts, who account for around seven of 16 on market data, show that many on the Street are not yet convinced by the case for a rebound.

What Should Investors Watch Next?

In the meantime, watch for further broker revisions that reflect the October changes, since the published average is likely to move as they are processed.

Align's Stale Averages Trail October Downgrades

Align closed at $142.71 on 9 October 2026, while both data sets display an average of about $199 that appears not to reflect a number of recent cuts. The latest named targets run from $155 to $209, and the latest actions point down, with Evercore downgrading to In-Line at $155 and Stifel cutting to $175 from $210. Ratings remain split between Buy and Hold, and with seven of 16 analysts at Hold in market data, the published average is likely to move as the October changes are processed.